Prevalence of malaria and anaemia among HIV infected pregnant women receiving co-trimoxazole prophylaxis in Tanzania: a cross sectional study in Kinondoni Municipality

Table 3 Prevalence of malaria according to selected risk factors among HIV infected pregnant women receiving co-trimoxazole (N = 420)

Characteristics	N	Malaria prevalence n (%)	P-value	AOR	95% CI	P-value
*WHO clinical stage*
Stage I	338	12 (3.6)		1
Stage II	43	2 (4.7)		0.851	0.171-4.226	0.844
Stage III-IV	39	5 (12.8)	0.031^a	2.305	0.699-7.597	0.170
CD4 count (cells/μL)*
≥500	104	4 (3.8)		-
350-499	85	3 (3.5)		-
200-349	96	8 (8.3)		⁻
<200	59	4 (6.8)	0.417^a	-
*Pregnancy trimester*
1st trimester	20	1 (5)		-
2nd trimester	206	9 (4.4)		-
3rd trimester	194	9 (4.6)	0.986^a	-
*Gravidity*
Primigravidae	139	6 (4.3)		-
Secundigravidae	148	5 (3.4)		-
Multigravidae	133	8 (6)	0.563^a	-
*Adherence to co-trimoxazole*
Good	208	2 (1)		1
Average	80	4 (5)		3.578	0.611-20.955	0.157
Poor	132	13 (9.8)	0.001^a	6.806	1.346-34.429	0.02
*ITN use*
Yes	380	15 (3.9)		-
No	40	4 (10)	0.096^b	-
*ART use category*
Prophylaxis	288	11 (3.8)		-
Life long	132	8 (6.1)	0.305^a	-

^aCalculated by Pearson Chi Square, ^bCalculated by Fischer’s Exact Test, *Results of CD4 count were available for only 344 subjects out of 420 (81.9%).

ISSN: 2050-6511